Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa

• Published in: PloS one 2014-10, Vol.9 (10), p.e107245-e107245
• Main Authors: Danel, Christine, Kabran, Mathieu, Inwoley, André, Badje, Anani, Herrmann, Jean Louis, Moh, Raoul, Lecarrou, Jérôme, Gabillard, Delphine, Ntakpe, Jean Baptiste, Deschamps, Nina, Ouattara, Eric, Perronne, Christian, Eholie, Serge, Anglaret, Xavier
• Format: Article
• Language: English
• Subjects: Adult; Adults; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Antigens; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; CD4 antigen; CD4 Lymphocyte Count; Clinical medicine; Conversion; Cote d'Ivoire; Enzyme-Linked Immunosorbent Assay; Enzymes; Epidemics; Female; Follow-Up Studies; Gold; HIV; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - immunology; Human immunodeficiency virus; Humans; Infections; Interferon-gamma - analysis; Isoniazid - pharmacology; Male; Medical diagnosis; Medicine and Health Sciences; Mycobacterium tuberculosis; Patients; Performance assessment; Research and Analysis Methods; Reversion; Therapy; Tuberculosis; Tuberculosis - complications; Tuberculosis - diagnosis; Tuberculosis - prevention & control
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0107245

To assess the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) test for active tuberculosis (TB) in HIV adults, and its variation over time in patients on antiretroviral therapy (ART) and/or isoniazide preventive therapy (IPT). Transversal study and cohort nested in the Temprano ANRS 12136 randomized controlled trial assessing benefits of initiating ART earlier than currently recommended by World Health Organization, with or without a 6-month IPT. Performance of QFT-GIT for detecting active TB at baseline in the first 50% participants, and 12-month incidence of conversion/reversion in the first 25% participants were assessed. QFT-GIT threshold for positivity was 0.35 IU/ml. Among the 975 first participants (median baseline CD4 count 383/mm3, positive QFT-GIT test 35%), 2.7% had active TB at baseline. QFT-GIT sensitivity, specificity, positive and negative predictive value for active TB were 88.0%, 66.6%, 6.5% and 99.5%. For the 444 patients with a second test at 12 months, rates for conversion and reversion were 9.3% and 14%. Reversion was more frequent in patients without ART and younger patients. IPT and early ART were not associated with reversion/conversion. A negative QFT-GIT could rule out active TB in HIV-infected adults not severely immunosuppressed, thus avoiding repeated TB testing and accelerating diagnosis and care for other diseases. ClinicalTrials.gov NCT00495651.